Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? - PubMed (original) (raw)
Review
Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
S Fiorucci et al. Biochem Pharmacol. 2001.
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a mainstay in the treatment of inflammatory disease and are among the most widely used drugs worldwide. They are anti-inflammatory, antipyretic, and analgesic and are prescribed as first choice for the treatment of rheumatic disorders and, in general, inflammation. The main limitation in using NSAIDs consists in their side-effects, including gastrointestinal ulcerogenic activity and bronchospasm. The mechanism of action of these drugs is attributed to the inhibition of cyclooxygenase (COX), and, consequently, the conversion of arachidonic acid into prostaglandins. It is hypothesized that the undesirable side-effects of NSAIDs are due to the inhibition of COX-1 (constitutive isoform), whereas the beneficial effects are related to the inhibition of COX-2 (inducible isoform). Arachidonic acid can also be converted to leukotrienes (LTs) by the action of 5-lipoxygenase (5-LOX). LTC(4,) LTD(4,) and LTE(4) are potent bronchoconstrictors, whereas LTB(4) is chemotactic for leukocytes and plays an important role in the development of gastrointestinal ulcers by contributing to the inflammatory process. Thus, developing dual inhibitor compounds that will simultaneously inhibit COX and 5-LOX could enhance their individual anti-inflammatory effects and reduce the undesirable side-effects associated with NSAIDs, especially of the gastrointestinal tract. The most promising COX/5-LOX inhibitor is ML3000 ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid), now in Phase III clinical trials. This new approach will certainly help to unravel the mechanisms at the root of the undesirable effects of NSAIDs and to develop safer NSAIDs.
Similar articles
- Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A, Ottani A, Sandrini M. Bertolini A, et al. Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872. Pharmacol Res. 2001. PMID: 11735348 Review. - The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
Celotti F, Durand T. Celotti F, et al. Prostaglandins Other Lipid Mediat. 2003 Jul;71(3-4):147-62. doi: 10.1016/s1098-8823(03)00039-x. Prostaglandins Other Lipid Mediat. 2003. PMID: 14518558 Review. - Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Bertolini A, Ottani A, Sandrini M. Bertolini A, et al. Curr Med Chem. 2002 May;9(10):1033-43. doi: 10.2174/0929867024606650. Curr Med Chem. 2002. PMID: 12733982 Review. - Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs.
Charlier C, Michaux C. Charlier C, et al. Eur J Med Chem. 2003 Jul-Aug;38(7-8):645-59. doi: 10.1016/s0223-5234(03)00115-6. Eur J Med Chem. 2003. PMID: 12932896 Review. - Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.
Celotti F, Laufer S. Celotti F, et al. Pharmacol Res. 2001 May;43(5):429-36. doi: 10.1006/phrs.2000.0784. Pharmacol Res. 2001. PMID: 11394934 Review.
Cited by
- Effects of Cashew Nuts (Anacardium occidentale L.) and Cashew Nut Oil on Intestinal Permeability and Inflammatory Markers during an Energy-Restricted 8-Week Intervention: A Randomized Controlled Trial (Brazilian Nuts Study).
Meneguelli TS, Wendling AL, Kravchychyn ACP, Rocha DMUP, Dionísio AP, Bressan J, Martino HSD, Tako E, Hermsdorff HHM. Meneguelli TS, et al. Foods. 2024 Sep 14;13(18):2917. doi: 10.3390/foods13182917. Foods. 2024. PMID: 39335845 Free PMC article. - New Thiazole Carboxamide Derivatives as COX Inhibitors: Design, Synthesis, Anticancer Screening, In Silico Molecular Docking, and ADME Profile Studies.
Hawash M, Jaradat N, Sabobeh R, Abualhasan M, Qaoud MT. Hawash M, et al. ACS Omega. 2023 Aug 6;8(32):29512-29526. doi: 10.1021/acsomega.3c03256. eCollection 2023 Aug 15. ACS Omega. 2023. PMID: 37599929 Free PMC article. - Comprehensive chemo-profiling of coumarins enriched extract derived from Aegle marmelos (L.) Correa fruit pulp, as an anti-diabetic and anti-inflammatory agent.
Tiwari R, Mishra S, Danaboina G, Pratap Singh Jadaun G, Kalaivani M, Kalaiselvan V, Dhobi M, Raghuvanshi RS. Tiwari R, et al. Saudi Pharm J. 2023 Sep;31(9):101708. doi: 10.1016/j.jsps.2023.101708. Epub 2023 Jul 25. Saudi Pharm J. 2023. PMID: 37564748 Free PMC article. - Dual synergistic inhibition of COX and LOX by potential chemicals from Indian daily spices investigated through detailed computational studies.
Rudrapal M, Eltayeb WA, Rakshit G, El-Arabey AA, Khan J, Aldosari SM, Alshehri B, Abdalla M. Rudrapal M, et al. Sci Rep. 2023 May 27;13(1):8656. doi: 10.1038/s41598-023-35161-0. Sci Rep. 2023. PMID: 37244921 Free PMC article. - Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review.
Sohail R, Mathew M, Patel KK, Reddy SA, Haider Z, Naria M, Habib A, Abdin ZU, Razzaq Chaudhry W, Akbar A. Sohail R, et al. Cureus. 2023 Apr 3;15(4):e37080. doi: 10.7759/cureus.37080. eCollection 2023 Apr. Cureus. 2023. PMID: 37153279 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials